CD8A and neoplasm: Unfortunately, daily 75 mg/kg BAY1082439 treatment led to significantly decreased tumor- and spleen-associated CD45+, CD8+ T and CD4+ T cell numbers (Fig. 2A, B; Supplementary Fig. 3A), which could be detrimental for T cell-mediated anti-tumor immunity even if cancer cell-intrinsic immunosuppression could be alleviated.